India to United States: Adalimumab Export Trade Route
India has recorded 1 verified shipments of Adalimumab exported to United States, representing a combined trade value of $1.0K USD. This corridor is served by 1 active Indian exporters, with an average shipment value of $1.0K USD. The leading Indian exporter is NIBA HEALTHCARE, which accounts for 100% of total export value with 1 shipments worth $1.0K USD. On the buying side, RIVER HAWKINS is the largest importer in United States with $1.0K USD in purchases. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Adalimumab corridor is one of India's established pharmaceutical export routes, with 1 shipments documented worth a combined $1.0K USD. The route is dominated by NIBA HEALTHCARE, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's adalimumab manufacturing sector.
Across 1 active suppliers, the average shipment value stands at $1.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 74% of all shipments, consistent with adalimumab's non-urgent bulk-order profile.
Shipment activity peaks during April–June, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 9.4%, placing it at rank #1 among India's top adalimumab export destinations globally.
On the import side, key buyers of Indian adalimumab in United States include RIVER HAWKINS. RIVER HAWKINS is the single largest importer with 1 shipments valued at $1.0K USD.
